Clinical pharmacokinetics of anti-angiogenic photodynamic therapy with benzoporphyrin derivative monoacid ring-A in dogs having naturally occurring neoplasms
Clinical pharmacokinetics of anti-angiogenic photodynamic therapy with benzoporphyrin derivative monoacid ring-A in dogs having naturally occurring neoplasms
复制标题
DOI：
10.1111/j.1439-0442.2006.00802.x
复制
发表时间：
2006-03-01
期刊：
影响因子：
--
通讯作者：
Fujinaga, T
中科院分区：
文献类型：
--
作者：
Osaki, T;Hoshino, S;Fujinaga, T
The aim of this study was to examine the pharmacokinetics of clinically applied benzoporphyrin derivative monoacid ring-A (BPD-MA; Verteporfin(R)), a second-generation photosensitizer, during a trial of photodynamic therapy (PDT) in nine dogs having naturally Occurring neoplasms. After injecting BPD-MA at 0.5 mg/kg intravenously, its mean half-life (t(1/2)) was found to be 8.14 +/- 5.34 h, rnean clearance (Cl) 35.13 +/- 9.62 ml/(h kg), the mean value of the volume of distribution (V-c) 0.08 +/- 0.01 l/kg and the mean steady state volume of distribution (V-ss) 0.38 +/- 0.31 l/kg respectively. With the exception of a transitional increase in serum alkaline phosphatase activity, no other clinical abnormalities were observed. The t(1/2) in dogs with naturally occurring tumours was longer than that in humans, but similar to that in rats. The values of Cl and V-ss in dogs having naturally Occurring neoplasms were lower than those in humans. It is suggested that the pharmacokinetics of BPD-MA in tumour-bearing dogs would be helpful in determining the protocol of a short drug-light interval PDT with BPD-MA that mainly targets the tumour vasculature.
